Working toward delivering a significant
improvement in the health and quality of life
to future generations living with XLHED
Edimer Pharmaceuticals
Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisors. The company is based in Cambridge, Massachusetts.
XLHED NetworkStay informed. Stay connected.
Register for the XLHED Network today.
Are you a woman who is a confirmed or suspected carrier of XLHED?
Would you like to be involved in XLHED research? Consider taking this survey www.surveymonkey.com/s/X-CORS
To learn about other studies we are conducting right now visit: clinicaltrials.gov
Edimer Appoints Dan Lynch to Company's Board of Directors
Read more >>
Edimer Announces Donation to National Foundation for Ectodermal Dysplasias at Mass. State House Celebration of Rare Disease Day
Read more >>
